Psyence Biomedical Ltd. Stock Price, News & Analysis

Psyence BioMed (Nasdaq: PBM) announced Bellberry Human Research Ethics Committee approval to use PsyLabs’ psilocybin product (NPX5) in its ongoing Phase IIb trial for adjustment disorder in cancer patients. The amendment covers all participating sites including Empax Centre, Mind Medicine Australia Clinic, and Paratus Clinical Research in Melbourne, and reflects updated protocol, investigator brochure, and participant materials.

The Phase IIb trial will enroll approximately 87 participants, test two therapeutic doses versus a low-dose comparator with structured psychotherapy, and is tracking to deliver top-line results in 2026. The company reports approximately USD $9.5 million in cash and no debt and emphasizes strengthened vertical integration, GMP manufacturing, and supply-chain control via its investment in PsyLabs.

Psyence BioMed (Nasdaq: PBM) CEO Jody Aufrichtig summarized 2025 clinical and corporate milestones and outlined 2026 priorities. Key points include:

• Initiation and dosing of first patients in a Phase IIb psilocybin-assisted psychotherapy trial for Adjustment Disorder in palliative care.
• Multi-million-dollar follow-on investment in PsyLabs to secure GMP nature-derived psilocybin and ibogaine supply and a reported breakthrough in high-purity ibogaine production.
• Regulatory momentum in Australia with a TGA public consultation that could enable supervised access via the Authorised Prescriber framework.
• Company finished the year debt free with over USD $9 million cash and plans to accelerate enrollment, expand manufacturing, and pursue longevity-focused indications in 2026.

Psyence BioMed (Nasdaq: PBM) launched a psilocybin longevity research program in collaboration with South African academic researchers, positioning the company as the first publicly listed firm to investigate psilocybin’s effects on biological aging markers. The initiative will test biomarkers for cellular stress, inflammation, mitochondrial function, telomere length and behavioural healthspan indicators under the leadership of Dr. Tanya Calvey, PhD. The company has commenced work and expects full acceleration early in the new year following ethics approval. The release cites preclinical findings including a >50% lifespan increase in human skin and lung cells with psilocin.

Psyence BioMed (Nasdaq: PBM) announced it secured a sustainable, high‑potency supply of iboga bark via partner PsyLabs to support clinical development of pharmaceutical‑grade ibogaine for substance use disorders and research markets.

The company received an initial 50 kg shipment being processed into ibogaine HCl and Total Alkaloid Extracts, with PsyLabs’ material described as GMP‑compliant. The collaboration emphasizes ethical sourcing, sustainability, and benefit‑sharing with source communities to build a vertically integrated supply chain for clinical research.

Psyence BioMed (Nasdaq: PBM) announced a strategic investment in PsyLabs to establish ibogaine operations and manufacturing in Africa, with PsyLabs operating an EU GMP-grade facility in Southern Africa.

The move gives PBM vertical integration across cultivation, extraction, and purification, positioning the company with traceable supply from the ibogaine source and control of quality for research and commercial development.

The release cites rising global momentum for ibogaine research, including a $50 million Texas research allocation in 2025 and recent pharmaceutical M&A activity around ibogaine analogs.

Psyence BioMed (Nasdaq: PBM) reported multiple patients have been dosed in its Phase IIb study of nature-derived psilocybin plus psychotherapy for Adjustment Disorder in palliative care.

The multi-site, double-blind, placebo-controlled trial is designed to enroll 87 patients across Australia with doses of 10 mg, 25 mg or a low-dose comparator of 1 mg. Patients have been dosed at the Empax Center in Perth and the Mind Medicine Australia Clinic in Melbourne, and Paratus Clinical Research has been activated to expand to a third enrolling site. Topline results are anticipated by year-end 2026.

Psyence BioMed (Nasdaq: PBM) made a USD 3,500,000 follow-on investment in PsyLabs on August 15, 2025, after an earlier USD 500,000 investment in April 2025. The investment secures PsyLabs as a primary supplier of GMP‑grade psilocybin and ibogaine for Psyence BioMed’s clinical programs and aims to ensure an ethical, sustainable supply chain for the company’s nature-derived psychedelic pipeline.

The partnership highlights Psyence BioMed’s strategic focus on integrated supply from Southern Africa and notes certain executives provide consulting services to PsyLabs and collectively own less than 5% of PsyLabs.

Psyence BioMed (NASDAQ:PBM), a biopharmaceutical company focused on nature-derived psilocybin and ibogaine therapies for mental health, will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025. The conference will be held at the Lotte New York Palace Hotel in New York City and virtually.

CEO Dr. Neil Maresky will present the company's business strategy and pipeline. The virtual presentation will be available on-demand starting September 5, 2025, at 7:00 AM EST. Additionally, the company will host a separate webinar featuring its Scientific Advisory Board on September 16, 2025, at 12:00 PM EST to discuss ongoing clinical development programs and strategic initiatives.

Psyence BioMed (NASDAQ: PBM) provided a comprehensive corporate update highlighting significant progress across multiple fronts. The company reported a strong cash position of $11.4 million with no outstanding debt and successfully regained Nasdaq compliance following a 1-for-7.97 reverse stock split.

Key developments include protocol amendments to expand patient eligibility in clinical trials, activation of three clinical sites, and advancement of their Alcohol Use Disorder (AUD) study. The company strengthened its strategic alliance with PsyLabs, achieving GMP-aligned Ibogaine Total Alkaloid extract production. PBM is positioning itself in the projected $3.3 billion psychedelics market by 2031, focusing on developing naturally derived psychedelic therapies for mental health conditions.